TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Median Time to Significant Analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Influenza infection severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in BOLD fMRI Signal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: morbidity rate of peri-operative cerebral hemorrhagic events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: morbidity rate of peri-operative cerebral ischemic events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of discrepancies between clinical history and OFEK system
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of patients in stable sinus rhythm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Objective Response Rates (ORR)
Endpoint domain: Physiological/clinical
Primary endpoint: Intratracheal pressure conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Prevalence of spatial discrimination threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Prevalence of temporal discrimination threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Prevalence of vibration-induced illusion of movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Prevalence of impaired kinesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean Percentage of Pad Weight Gain Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in whole-body insulin sensitivity (M-value)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Safety and tolerance evaluated by incidence, severity and outcomes of AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in a composite clinical-lab score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with adverse events (AE) / serious adverse event (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Youth Perceived Burdensomeness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean Blood Glucose (BG) in mg/dl
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Patients With New Vertebral Fractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in McGill Pain Questionnaire - Short Form
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Change in VAS
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Attrition at 3 months
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Postprandial GLP-1 plasma levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: AUClast of Plasma Budesonide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCinf of Plasma Budesonide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of Plasma Budesonide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: quadriceps endurance time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: abnormal laboratory examinations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: APAIS score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: HIFU induced tissue necrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction volume of fibroadenoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Developmental outcome
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Frequency of gluten exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional outcome
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Body image and cosmetic measurements
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Pediatric quality of life multidimensional fatigue scale
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Presence of anastomotic airway complication
Endpoint domain: Adverse events/effects
Primary endpoint: Symptomatic outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Supply costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Hospital Readmission Rates
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Number of post-operative complications
Endpoint domain: Adverse events/effects
Primary endpoint: Number and degree of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change of ASIA motor score from baseline at 24 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Change in fMRI BOLD signal during tasks of reward
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in fMRI BOLD signal for control reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in fMRI BOLD signal for cue reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in MRI Voxel-Based Morphometry (VBM) measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Expression of sensory receptors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Sputum expectorated
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Maternal and newborn viral titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Maternal and newborn antibody titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Placental morphology and histopathology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tPA-PAI-1 Complex rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time in seconds required to make the 11 cuts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Efficacy of the two timing regimens
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trilineage hematologic response rate (CR + PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Radiographic resolution of hematoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: 24-hour fecal wet weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percent Change of Triiodthyronine Over Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change From Baseline in Mid-Face Volume Deficit Scale (MFVDS) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eczema Area and Severity index (EASI) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Objective Response Rate (ORR) Per RECIST v1.1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of COPD Exacerbation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Maximal Tolerating Dose (MTD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of analgesic effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: degree of postoperative mitral valve regurgitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change Modified Ashworth Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change Berg Balance Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change Dynamic Gait Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients who has clopidogrel HTPR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of patients who are carriers of CYP2C19 loss-of-function alleles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients who are carriers of P2Y12-receptor loss-of-function alleles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of patients with improved Creatinine level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Percentage of participants without virologic failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in fMRI Blood-oxygen-level-dependent Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Cognitive Function Measured by Neuropsychological Testing
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Structural changes in white matter pathways
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in resting state activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Total Difficulties Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Rate of CPR in the pathology specimen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to testing schedule
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Sedation Scale Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time From Administration to Discharge
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Postoperative complaints
Endpoint domain: Adverse events/effects
Primary endpoint: Lid-parallel conjunctival folds (LIPCOF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Client Satisfaction with Vocational Services
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Practitioner perceived competency
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Infant negative emotionality
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: epileptic foci
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Postvaccination Measles Antibody Titer ≥255 mIU/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Postvaccination Mumps Antibody Titer ≥10 Ab Units/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Postvaccination Rubella Antibody Titer ≥10 IU/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Postvaccination Varicella Antibody Titer ≥1.25 and ≥5 gpELISA Units/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Acceptability of audio-recording of consent discussions
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Utility of audio-recording of consent discussions
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Average reduction in HbA1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area under the serum insulin concentration time curve from 0 to 10 minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Area under the serum insulin concentration time curve from 10-120 minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Proportion of Subjects Who Achieve Major Molecular Response (MMR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radionecrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: autoantibody recurrence frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: autoantibody levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: phenotype of autoreactive T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in patient's quality of life (QoL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percentage of radioactive dose excreted in urine and faeces
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cmax of plasma and blood radioactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC Last of plasma and blood radioactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of grade ≥3 neutropenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Anti-HBs seroprotection rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Sensitivity of rapid urease test for detection of H.pylori
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of Participants Improved as Measured by the Clinical Global Impression-Global Improvement Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean Post-baseline Aberrant Behavior Checklist Irritability Subscale Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curve (AUC 0-360) for TI Inhalation Powder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curve (AUC 0-360) for RAA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in 12-hour Reflective Total Nasal Symptom Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of infused autologous units of LyP
Endpoint domain: Adverse events/effects
Primary endpoint: Possible LyP adverse reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Change in levels of circulating triglycerides
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: tumor reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Concordance of fluid volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completion of dental procedure without rescue injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Patients With In-hospital Initiation of Medication for OUD or AUD
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Patients With Linkage to Follow-up Care for OUD or AUD
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Patients With Heavy Drinking in Past 30-days at Follow-up Among Patients With Alcohol Use Disorder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change from baseline in aBMD of the proximal femur and lumbar spine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Type 2 diabetes management
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Increased number of bowel movements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Occurrence and intensity of solicited local or general symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Feasibility as Measured by Number of Participants Accrued to the Study Within 16 Months
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Participants Who Adhere to at Least 80% of the Study Protocol
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Acceptability as Measured by the Client Satisfaction Questionnaire (CSQ) 8-item Version
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: de novo or worsened obstructed defecation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Arm, Shoulder and Hand questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: % patients achieving ATP III goals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Decreased venipuncture Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Facial recognition performance change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Multi-tasking performance change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TRX518 peak concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnosis of LAA thrombus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CDAI response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in serum IGF-I concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of patients with abnormal GH stimulation tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Occurrence of restrictive lung disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Occupancy at 5-HT1B receptors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Adverse events and serious adverse events assessments
Endpoint domain: Adverse events/effects
Primary endpoint: Quality of Life satisfaction percentage
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: composite of death (all cause-mortality), MI and stroke
Endpoint domain: Mortality/survival
Primary endpoint: Differentiation between murale nodules and mucus clots or debris
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinician Administered PTSD Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Time Line Follow Back (TLFB)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: CR-rate after therapy with GO-A-HAM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma AUCinf
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postprocedure Platelet Count Following Donation of Single Platelet Product
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Postprocedure Platelet Count Following Donation of Double Platelet Product
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Reflux Episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Inhaler technique scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall survival in months
Endpoint domain: Mortality/survival
Primary endpoint: Time of complete data transfer
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percent of Participants With Depression Remission
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in K-MMSE
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in total circulating 25(OH)D concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in total circulating 25(OH)D concentration in COVID-19 positives
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in SARS-CoV-2 antibody titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: brachial flow mediated dilatation (FMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: carotid pulse wave velocity (c-PWV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: reactive hyperemia index (RHI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: β-stiffness coefficient
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Progression-free survival (PFS) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Activation of beige/brown adipose tissue - Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Activation of beige/brown adipose tissue - Temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Activation of beige/brown adipose tissue - Adipokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Activation of beige/brown adipose tissue - Activation Genes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic Value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants who died during the intervention
Endpoint domain: Mortality/survival
Primary endpoint: Migraine Relief at 2 Hours Post Stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes